This action might not be possible to undo. Are you sure you want to continue?
Use ISSN#1078-6791. To subscribe, visit alternative-therapies.com
Stanislaw R. Burzynski, MD, PhD: Novel Cancer Research and the Fight to Prove Its Worth
Interview by Karen Burnett Stanislaw R. Burzynski, MD, PhD, graduated with distinction from the Medical Academy in Lublin, Poland, in 1967. During the same year he identified naturally occurring peptides in the human body which he concluded control cancer growth. He found that there is a marked deficiency of these peptides in cancer patients. In 1968, he earned his doctorate in biochemistry. From 1970 to 1977, while a researcher and assistant professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and coauthored 16 publications, including five concerning his research on peptides and their effect on human cancer. Four of these publications were also coauthored by other doctors associated with MD Anderson Hospital and Tumor Institute and Baylor College of Medicine. It was at Baylor that Dr Burzynski named these peptides “antineoplastons” due to their activity in correcting and normalizing neoplastic, or cancerous, cells. In 1977, Dr Burzynski founded his clinic in Houston where he’s since treated over 15 000 patients. He is also the president of the Burzynski Research Institute, where he continues to pursue scientific research on antineoplastons. He is the author and coauthor of over 300 scientific publications and presentations. He holds 242 patents registered in 35 countries, related to proprietary scientific inventions. Alternative Therapies in Health and Medicine (ATHM): Please tell us about your education in Poland and how you became interested in researching the science of cancer. Dr Burzynski: In Poland, my main interest initially was biochemistry. When I entered medical school, I was determined to proceed with research in biochemistry at the same time as I was studying medicine. Before I even started at the Medical Academy in Lubin, Poland, I was quite involved in chemical experimentation. During my high school days, I spent a lot of time in chemical laboratories and participated in something called Chemical Olympics, which was the high school students from all over the country competing once a year. I was able to go to the top of these Olympics at the national level. So I carried a lot of interest in chemistry since the high school years and, obviously, wanted to continue this in my medical university. And that’s what I did from the first grade of the curriculum, or first class. And I was very fortunate because after I graduated—after I finished my first grade, the professor offered me the position of teaching assistant, which was very unusual—a second-grade student also teaching grade-one students. I was giv54
ing lectures. I was participating in practical exercises in chemistry and so on. At the same time, I began receiving a substantial salary, which was also very unusual. So during my medical education, I also was able to be quite productive in the area of biochemistry. When I came to the end of my medical education—I graduated in 1967 and received a diploma with distinction, first in the entire class—I had published a number of publications in international biochemical journals. At that time, I had edited about 14 publications and had presented abstracts at congresses. So it was logical that I should do a doctoral dissertation, which again was very unusual. In the European tradition, you do this many years after graduation from medical school—probably 15 or 20 years—after you already have a lot of experience. Since I already was quite advanced in the research, I proceeded with doctoral work. It was during this work that I discovered new chemicals in human blood. I was working on amino acids in blood, but I discovered additional chemicals, which were giving similar reactions to amino acids, and I identified them as peptides. Nobody before knew that these peptides ever existed in blood; I was the first one to discover them. Since I was approaching my examinations for the doctorate and public defense of the doctoral dissertation, I wanted to make sure that I further identified these peptides, which nobody knew before. I was afraid that I would have some tough questions from the professors during my defense and also during public presentation of my work. So I proceeded further in the identification of these newly discovered chemicals and found that they were almost deficient—they were almost completely gone—in the blood of patients who had advanced cancer. This was the first time I found some correlation between cancer and the newly discovered chemicals existing in normal human blood. Logically, I thought that such deficiency in advanced cancer patients perhaps had something to do with anticancer activity of these newly discovered peptides. But at that time, in Poland there were not enough resources to study this further. So I successfully obtained the doctorate in biochemistry a year after my graduation from medical university and proceeded in my work to characterize these newly discovered peptides. By the time I came to the United States in 1970, I already had found 39 peptide fractions in blood. I brought with me the samples and I was looking for the possibility to test these samples for their
Conversations With Stanislaw R. Burzynski, MD, PhD
ALTERNATIVE THERAPIES, MAY/JUNE 2012, VOL. 18, NO. 3
please visit copyright.This article is protected by copyright. —Stanislaw R.com I discovered new chemicals in human blood. Burzynski. I was working on amino acids in blood. … Nobody before knew that these peptides ever existed in blood. … I proceeded further in the identification of these newly discovered chemicals and found that they were almost deficient—they were almost completely gone—in the blood of patients who had advanced cancer. but I discovered additional chemicals. which were giving similar reactions to amino acids. visit alternative-therapies. MD. To share or copy this article.com. PhD . I was the first one to discover them. To subscribe. and I identified them as peptides. Use ISSN#1078-6791.
in 1977. This enabled me to move further and to try to put together an application for a grant through the National Cancer Institute (NCI). So this was great luck that I was offered a position in one of the top centers doing peptide research in the country. colon cancer which spreads to the liver. but I was the one who was supposed to direct the grant and give them certain tasks to perform. And there was a case of bladder cancer. So the first study was a great success. I had just come to the country and could barely communicate in English. of course. was very interesting. on the first formulation of Antineoplaston A. which was also very advanced. Twelve Oaks Hospital. 3 . what was even more important was that the professor who employed me. I continued research at Baylor on peptides with anticancer activity. This was very gracious. which means that the tumors disappeared completely—very unusual for a phase I clinical trial. And we discovered that it could be done. MAY/JUNE 2012. We are no longer using this. I met with my friend from MD Anderson Cancer Center. Even Conversations With Stanislaw R.This article is protected by copyright. This was his work and. Ultimately. Peptides that existed in blood were filtered through the kidneys into urine. which I learned by myself. these peptide fractions did not have any toxic effect. and I immediately started work on both brain peptides and peptides from the blood. it has nothing to do with urine. which was remarkable because such a thing did not exist before. but at the same time he agreed that I could spend about 50% of my time working on my peptides that I discovered in Poland. and we could have a lot of urine for my study. At the same time. this was the material that was readily available. PhD ALTERNATIVE THERAPIES. please visit copyright. NO. I was able to make contact with the doctors from MD Anderson Cancer Center and they volunteered to test my peptide fractions on various cancer cell lines. about when President Nixon proclaimed the war on cancer. obviously.com biological activity. I received substantial resources and was able to hire additional researchers to work with me. The day after my birthday in 1971. My colleagues at MD Anderson were twice my age and they were wellknown professors. available material for isolating these peptides. visit alternative-therapies. The operation developed very well and I received a promotion to assistant professor at Baylor College of Medicine. we are simply obtaining them through the process of chemical synthesis. but it was very difficult to cap a sufficient amount of blood for such research. Initially. our attackers don’t stop. I have constantly been accused of using urine for treatment of patients. Finally. So that.com. Upon advice of Professor Ungar who was my boss at Baylor at that time. These are synthetic chemicals which are the same as those that exist in human blood. and I felt somewhat humbled by this. a remarkable thing occurred. and for the next 5 years. It belonged to American International chain of hospitals. to synthetic antineoplastons. But I realized that I would be medically attacked for using urine for isolation of peptides—the perception of urine was quite ugly—but on the other hand. initial phase I clinical trials were performed a long time ago. he found activity against cancer—various types of cancer which were very resistant to any therapy. 18. I isolated peptides from blood. MD. Burzynski. This was at the beginning of 1971. I began studying urine samples to see if we could isolate similar peptides from urine. How have your cancer patients responded to the treatment? Dr Burzynski: Well. I gave him the samples and as he began testing. Since 1980. ATHM: Despite controversy in the medical community and years of legal harassment by the board of medical examiners and the FDA. So I decided to proceed and isolate the peptides from urine. the grant which I received from the NCI was for further characterizations of peptides from urine which have anti56 cancer activities. However. we have done a lot of research on synthetic antineoplastons and decided to discontinue research on fractions isolated from urine. Despite this. This was done together with the doctors from MD Anderson. Such opportunity occurred in October of 1970 when I was given the position of research associate at Baylor College of Medicine in Houston. which were the objects of the first clinical trials. These were tough cases: for instance. January 23. and urine was a much easier. There were 22 patients in phase I and four of them developed what is classified as complete response. is how it happened. Finally in 1972. we proceeded with further characterization of antineoplastons and I was able to reproduce at least some of these ingredients synthetically. the results of your research into antineoplastons as a treatment for cancer has progressed to phase III clinical trials. It’s been a long road to get to this point. I received a grant from the NCI to study the peptides. Every sample he tested. such as malignant melanoma. They did not kill normal cell lines. Obviously. To subscribe. The study was done at one of the top hospitals in Houston. The journal which published the results put the picture of the liver scan showing remarkable decrease of large metastatic tumors on the cover. But then. but the results were quite remarkable. Use ISSN#1078-6791. Dr Georges Ungar. in summary. Again. I was able to build a substantial laboratory with new equipment. I became principal investigator in the grant. To share or copy this article. VOL. Then our attention switched from fractions isolated from urine. wanted me to do research on peptides isolated from the brain.
The most important thing is that we are saving the lives of numerous people. About 35% of patients who did not have prior treatment and were diagnosed with inoperable brainstem glioma survived over 5 years. People usually survive between 1 to 2 years then they die. If the medical board would have received what they wanted in 1994. This harassment was dragging on for many. Japanese researchers presented the results of a controlled randomized clinical trial with patients who had advanced colon cancer which had spread to the liver. vs 6. One group was treated with chemotherapy administered directly into the liver. which is coming to the end. This always happens when you’re approaching medical breakthrough and we are prepared to handle this. Fourteen phase II clinical trials are completed involving patients with incurable brain tumors who have successfully proven safety and efficacy. which means that survival of the antineoplaston group was about 62%. The record is over 25 years. and in the group that received just the chemotherapy. So this translates to human lives. So the FDA granted us permission to proceed with phase III trials of brainstem glioma. But at the same time. visit alternative-therapies. For the first time in medical history. that’s stupid people motivated by some business or organization to slow us down. Use ISSN#1078-6791. such as the Texas Medical Board. If they win the right to discipline me. so it’s not easy. Of course. We have two patients with this type of tumor who are well and alive after 25 years without any sign of tumor.com now. there were twice as many patients alive after 5 years. We also see substantial survival over 5 years—above 35%.it was proven that this type of tumor can be cured. You really always have to have legal defense. state level. about 120 survived over 5 years. you have to definitely try to stay alive and preserve enough money to do advanced clinical research. these fourteen phase II clinical trials on incurable brain tumors. In 1984 we came out with the formulations of two intravenous antineoplastons. 3 . The other group received a combination of antineoplastons plus chemotherapy. PhD ATHM: Has antineoplaston treatment been better suited to certain cancers? Dr Burzynski: Our emphasis was brain tumors. mAY/JUNE 2012. The patients who received radiation were dying later on from the tumor or from the delayed effect of radiation therapy. MD. Now we are at the end of this project. we are very busy with brain tumors. In the antineoplaston group. Both versions have been used in a large number of phase II clinical trials supervised by the FDA. 18. But still. you see. To share or copy this article. then these 120 patients who have now survived over 5 years with malignant brain tumors wouldn’t survive today. but at the same time they informed us that we have to use antineoplastons plus radiation therapy. federal level. We are saving lives of people. Survival for children after diagnosis is usually 2 years.This article is protected by copyright. and that’s what we like to do here. Conversations With Stanislaw R. To subscribe. Dirty politics and harassment by agencies like the Texas Medical Board translate into human lives. please visit copyright. So that’s where we stand now. Now we have only one phase II clinical trial.7% when the patient is using radiation therapy. the FDA persists in not permitting us any other type of clinical trials other than antineoplastons plus radiation therapy. many years. We are attacked all the time by governmental agencies starting from county level. Recently. which is obviously remarkably higher. the more vicious the attacks on us become. VOL. They will die. ATHM: Did you have setbacks that caused you to change your treatment course? Dr Burzynski: Well. ATHM: Were there many patients that experienced this result? Dr Burzynski: This is not one patient. The closer we come to the final victory. We are still being attacked by state agencies. And today nothing comes even close to such statistics because these tumors are uniformly deadly. A travesty of justice. NO. Only about 6% survive longer than 2 years and none survive over 5 years if the standard treatment is used with radiation therapy. The “war” with the FDA lasted 14 years. We picked out the worst possible type of cancer for such clinical trials which is uniformly less than deadly.com. In the future. This should not happen today in the United States. and then we move into phase III clinical trials. They would be dead because I would not be able to treat anybody. and whenever we have the best results. 57 ALTERNATIVE THERAPIES. which I named Antineoplaston A10 and Antineoplaston AS2-1. we are exposed to the fiercest attacks ever by the agency which should award us for saving the lives of hundreds of incurable cancer patients. other groups were performing clinical trials on different types of cancers. these are numerous patients. The “war” with the Texas Medical Board began around ‘84 and is still in full steam. you have to go to court. If the patient is surviving over 20 years without any sign of tumors. despite any treatments which have been used. But it’s nothing unusual. So our adversaries never cease. how can you call it anything else? The patients have been cured. Out of these 550 patients. they lived much longer. Burzynski. they blame me for using urine in the treatment of patients. the attacks greatly intensified after the FDA gave us permission for phase III clinical trials. which is a large number of patients considering that they were diagnosed with an incurable disease. it was about 34%. It was very. very difficult. The patients who didn’t have any treatment. and they are not finished. we treated about 550 patients in FDA-supervised clinical trials. we will start additional clinical trials in the other types of cancers. We continued to develop a number of formulations and entered phase I with synthetic medication and then proceeded with phase II clinical trials. inoperable brainstem glioma. and at the same time. Our survival at 2 years is 56%. We know very well that patients who previously used antineoplastons after radiation therapy had much shorter survival. We did a lot of testing before that and also published the results. If we look into our project of phase II clinical trials which we did in brain tumors. The Japanese researchers also presented the results of clinical trials in primary liver cancers as well as some studies on lung and breast cancers and brain tumors. Five years is usually the milestone for saying that the patient was cured from the disease. certainly. the attacks intensify. but at this moment. and many patients survived over 10 years and 15 years. and the FDA also gave us what is called Orphan Drug Designation for all gliomas and these are all types of malignant brain tumors. then 400 patients who are under treatment now would have nowhere to go.
At that point they were saying “Wow it’s a great medication. or are you forever discouraged by your experiences? Dr Burzynski: We see numerous pharmaceutical companies. Obviously we don’t have good relations with them at all. This is very. The treatment was discontinued after 1 or 2 months. They gave them dosages which were about 50 times lower. 3 . NCI initially sponsored the clinical trial with Elan Pharmaceuticals focusing on one of the ingredients of antineoplaston. And we are working now with pharmaceutical companies. I defended myself against the ridiculous attacks of the FDA and then we finally proved that this was completely frivolous. I think they gave the institute about $15 million. and finally. ATHM: Clearly the pharmaceutical company played a role in the discrimination your company has faced. MD. Clinical trials did not start until 2 years later. PhD 58 ALTERNATIVE THERAPIES. They got together with the NCI. some others would like to work with you. by giving the patients very low dosages of the medication. they decided to get out of the agreement. together with the pharmaceutical company. But still the animosity lasts. it’s working. I had to continue with my own resources.com ATHM: How has your relationship with the NCI changed over the years? Dr Burzynski: Initially the relationship was good because we received a grant from the NCI. Then when the grant money stopped. was steal my invention. It is obvious that I would not be able to develop such a big project globally without support.. NO. They diluted the medications with sterile water. But then you have the pharmaceutical company ingredient. didn’t work. the FDA gave us approval of the prescription Conversations With Stanislaw R. and the NIH copied about 12 or 14 of these patents. I had no way to proceed with my research. visit alternative-therapies. but what they were trying to do instead. We were the subject of numerous grand jury investigations. they were saying that the treatment was great—on the other hand. the NCI did whatever they could to make sure that the trials would not be successful. To share or copy this article. And this group of experts really found remarkable results. please visit copyright. In the meantime. But after Elan Pharmaceuticals learned what we had. So then they decided to work against me with the FDA. That’s what they do. If there was any case in history that conspiracy of the government and pharmaceutical companies is documented. Some of them would like to steal. The trials had a difficult start. They published the results in the Journal of the National Cancer Institute and after the visit. of course. very well documented. which wanted to work with us to sponsor clinical trials to speed up the approval process. they were trying to put me in prison for life so that they could steal it from us. After we learned that what they did—and we had evidence because they measured the concentration of the ingredients of the antineoplaston in the blood—we forced them to stop after e Were the subject of numerous grand jurY investigations.” At the same time they were saying that the real antineoplastons. There were 243 patents for my inventions. Finally in 1990. In the patent for one of the ingredients of antineoplastons. and they continue to smear us whenever they can. 18. this is the case. Burzynski. one of our companies became a pharmaceutical company because a few months ago. The patients then developed side effects such as fluid overload.com. We were approached at the same time by Elan Pharmaceutical. They made the agreement. which included three additional ingredients. I used our attorneys to force them to stop because we didn’t want them to kill people just to prove that the antineoplastons don’t work. We need the participation of pharmaceutical companies to expand research.i defended mYself against the ridiculous attacks of the fda and then We finallY proved that this Was completelY frivolous. This is bad because they have to protect the American people. they wanted me to go to prison for life so that they could steal my invention. They were smearing us wherever they could. To subscribe.This article is protected by copyright. On one hand. We obviously were delayed. He became deputy commissioner of the FDA. and this provided valid answers to claims that the treatment failed. VOL. Use ISSN#1078-6791. they sent a group of experts to review select cases of brain tumors. Do you think you will ever partner with a company. We were very happy with this. MAY/JUNE 2012. The doctor who worked with us at NCI suddenly went to the FDA. And then. the NCI doesn’t like it. the NCI decided to sponsor clinical trials with antineoplastons in brain tumors. The NCI was out to take away what I discovered and go together with Elan for monetary award. W treatment of nine patients. How could they do it? Well. That’s what happens. How can we have good relations with thieves? Of course most of the people who were at the FDA at the time are no longer there.. and once they started. They had never seen such great results in the treatment of brain tumors.
So we know what to do because we have used this for a long time. The patient may receive dietary support to increase potassium in their blood. VOL. But in the meantime. the dosage could be different for a highly malignant brain tumor like glioblastoma and different for a tumor that is less active like low-grade glioma. We only incurred huge expenses because of the stupid actions of the governmental agencies and that’s where we are now. Burzynski. We need to identify 59 ALTERNATIVE THERAPIES. most of them are treated in our oncology practice. there is a tendency toward lower potassium levels in blood and higher sodium levels. it was always done this way. and finally. But it was not understood yet at that time that cancer is a disease of the genes. and this is the most effective treatment. The other way is orally in tablet form. but Conversations With Stanislaw R. in our oncology practice where most of the patients are treated. Do not treat just the name of cancer.com. then this money probably would come from the government. we are using medication which is approved by the FDA. at times. but 20 years ago. Since phase II clinical trials now are coming to an end. But in this case.com drug from the family of antineoplastons. In medical history. Only recently have the doctors become the slaves of organizations like the NCI or pharmaceutical companies. For instance. 18. This is called gene-targeted therapy. I still have to deal with character assassinations from people working for the pharmaceutical cartels who have a lot of support from organizations which should help us but instead. the patient receives a lot of intravenous fluid. insurance covers the treatment which is done here. When intravenous antineoplastons are given. For instance. “Well. ATHM: How does the lack of governmental support affect your patients? Dr Burzynski: When patients come to us. To share or copy this article. as well as [introducing] some supplements. so the main side effect is the disturbance of fluid balance and changes in mineral concentration. for practically every patient who comes for the treatment. We try to help obtain payments from the insurance companies for them—they have insurance policies and for most of them. we ask the FDA for permission in order to treat this patient. MD. and they are currently giving permission for the patients who didn’t have prior radiation or chemotherapy. We have to use a combination with the other medications because the activity of the oral antineoplastons is not as strong as intravenous. and we have a lot of experience. So this is severely limited. When the patient comes. So it’s just up to the FDA. ATHM: What are the side effects of intravenous antineoplaston treatment? Dr Burzynski: There are some mild side effects. 3 . To subscribe. Plus.This article is protected by copyright. ATHM: Do you use different doses and different components or make-ups for the treatment? Dr Burzynski: Absolutely. It’s going to be this way and then everybody will say. It can be done. that’s why we need to have a personalized approach. we spend $5 to $6 million for this purpose. mAY/JUNE 2012. One is intravenous. And that’s typical when the paradigm shift happens. It’s called Compassionate Exception. when the treatment with intravenous antineoplastons will be approved by the FDA—and in many other countries—the controversy will disappear. ATHM: Let’s talk about the science again. Annually. The cancers have names like breast cancer or lung cancer but what is really causing cancer is abnormality in our genes. ATHM: Could you please describe the genomic and epigenomic principles behind your more recent research and their involvement in your cancer treatment program? Dr Burzynski: I published the review article in a peer-reviewed journal almost 20 years ago on the principles of personalized gene-targeted therapy. Obviously. But these things can be very easily corrected by simple adjustment of the fluid volume the patient is taking. Use ISSN#1078-6791. ATHM: Do you recommend that your patients avoid chemotherapy and radiation before treatment with antineoplastons? Dr Burzynski: Well. we have to ask the FDA for permission to treat them. which costs us a lot of money. which is converted into one of the antineoplastons in the patient’s liver. The right way to treat cancer is to treat the genes that are causing the cancer. Now everybody knows about it. If you are talking about antineoplastons clinical trials. PhD unfortunately intravenous antineoplastons are limited to clinical trials. it is obvious. please visit copyright. I would try to treat these patients without radiation or chemotherapy because radiation and chemotherapy for brain tumors can do a lot of damage. We are gradually moving in this direction. NO. we ask FDA what they will allow us to do. So the supplement will have no additional side effects compared to the side effects of chemotherapy. We have protocols for clinical trials and we know which dosage we need to use for certain indications. now we are at the mercy of the FDA. There are no long-term side effects—after the treatment is completed. They don’t give permission for any other diagnosis—just for brain tumors.” The people who hated us suddenly try to become the friends. We are independent and can do whatever we would like to do without being manipulated by the other agencies. On the other hand. ATHM: Have you received any governmental financial help or partnerships? Dr Burzynski: We didn’t receive any. all of this disappears. we use other medications which work on the genes. visit alternative-therapies. we provide medication free of charge. How do you administer antineoplastons? Dr Burzynski: There are two ways to do it. This is phenylbutyrate. Also for children and adults the dosage is different. want to put us out of business. But instead we have to generate the money through our business activities and use this money for the approval process. We prefer to use intravenous antineoplastons because they have much higher activity. If you have support from the government. very few people realized it. Every case is somewhat different.
The crowd of oncologists learns the medicine by heart without understanding of what’s going on. you receive results suggesting that vitamin D could be quite helpful for one patient. Do not treat just pneumonia by the same antibiotics. But then if you learn how to use the proper switch to activate the gene then you have a powerful weapon against cancer. The first medication which worked on genes was Herceptin for the treatment of breast cancer. this approach still persists. We can also identify the medications which should be avoided because they are unlikely to work. ATHM: So is this what you mean about driver genes and designer treatment for your patients? Dr Burzynski: Yes. For instance. We are dealing with 700 000 existing ingredients which have pharmaceutical activity. That’s what we pioneered. visit alternative-therapies. and certainly you have chemicals which could be very effective in the treatment of cancer. To share or copy this article. Diet is a combination of chemicals. please visit copyright. this is not sufficient. And then we can have success. MD. And this is something that is easily understandable. This is foolish. and we need to add additional medications which are now available which work on other genes. And also they turn off oncogenes. very few medications could work on genes at that time. But suddenly a year ago. So now there’s the beginning of big change. There are over 40 medications that are available now. PhD ALTERNATIVE THERAPIES. you also find out which dietary ingredients make sense and which do not make any sense because they also work on the genes. Some doctors feel now that perhaps in 10 years oncology will completely change and every patient will have genomic analysis and be treated with a different plan which is designed for him.” If we are successful. scientific approach toward treatment of the genes. It’s not so difficult to understand. To subscribe. there is no financial burden for the patient. Herceptin was approved for the treatment of stomach cancer. But after a number of years. The genes can be mutated. it is. If you identify which patients will benefit from a particular medication. But it’s not diet as such. they have started to realize that there is a need to identify what is causing cancer in every patient who is coming for treatment and to use the right combination of medications. That’s what we use in our practice. and they send us the result. The laboratory runs the analysis of gene activity for the entire genome of 24 000 genes. If the patient has abnormality of the gene on which Herceptin works. 20 years ago. oncologists will attack you if you try to use Herceptin for something else. but identify the germs which cause pneumonia and treat the germs. Burzynski. ATHM: And do you provide genomic analysis for your patients? Dr Burzynski: No. Usually. rather than just treating the name of the disease. But what is not so understandable is that there is a system of genomic switches—called epigenome—which can switch off the activity of the gene or turn the gene on without changing the structure of the gene. The sample is sent to this laboratory. Unfortunately. some other chemicals may promote cancer. We need to identify these genes. It may happen that the same genes may cause breast cancer or stomach cancer. It was suspected some time ago that it will take 30 years to introduce such change. When you run genomic analysis. they were used for the treatment of infections such as pneumonia or kidney infections or whatever. the doctors realized that what they need to do is treat microorganisms which are causing the infection rather than the name of infection.com changes in the genes and treat the genes which are “sick. In order to do it right. ATHM: Do you find diet and supplements effective in treatment of cancer? Which supplements do you recommend to patients? Dr Burzynski: Diet is a combination of chemicals. Use ISSN#1078-6791. Some of these chemicals were isolated and now are available as chemotherapy drugs or gene-targeted therapy. recognized by the NCI.com. Antineoplastons are genomic switches which work on about 100 different genes that are crucial in development of cancer. then we can identify the medications which are the best combination for this particular patient. very. Once he receives the results. and then we would use the same medication for one patient’s breast cancer as well as another’s stomach cancer. Certainly. This is a complete analysis of the entire genome of 24 000 genes to find out which genes are active and which genes are not active. every patient who comes to the clinic is advised to have genomic analysis of tissue taken from the tumor. we have a totalitarian approach toward treatment: Everybody should receive the same regimen for the same name of cancer. It contributes to billions of dollars in losses because typically the medications—single medications— work for less than 10% of patients. 18. which work on different genes. which are causing cancer. When antibiotics were introduced for the first time. What is needed is a rational approach. We identify the genes which are causing the problem and treat the genes. But of course. then we can have very good results. and it may lose the activity. When you use genomic analysis. it can work very well. they run the test. They turn on the genes which fight cancer. NO. 3 . MAY/JUNE 2012. Now the same principles are being applied to the treatment of cancer. But this is really the science that is developing. That’s how it works. And it’s covered by insurance. I have been attacked by the Texas Medical Board for going overboard and using a logical. And frankly speaking. VOL. this is tissue which was obtained when the patient had biopsy. Some of these chemicals may help us to fight cancer. you also receive indication of which dietary ingredient could be helpful. They can also be amplified. for some other cancers. That’s why we have great success in the treatment of incurable brain tumors. you can have good results and you can save a lot of money. You have to know what to do. However. The silenced gene which was inactive now becomes active and will fight cancer. and they can be used in combination with antineoplastons. and that’s how we got substantial success. We try to use 60 the group of medications which work as genomic switches. But unfortunately. This is done by one of the best laboratories in the world. this was heresy. You have some other genes involved in cancer. Even today.This article is protected by copyright. and this is not the same when the gene is mutated. Or you receive another suggestion—this patient absolutely should avoid dietary ingredients which contain too much Conversations With Stanislaw R. The gene may be turned off by epigenomic mechanisms.
Some of the brightest oncologists are working together with us. as a general rule we have to avoid free sugars because they are used to produce energy in cancer cells. We would like to improve the activity and make the treatment much easier. you must look for driver genes—genes which are crucial to the development of cancer. PhD ATHM: Has your research taken on any new directions lately? Dr Burzynski: Yes. VOL. I have no doubt about it. They hate to see our good results. We are talking about the brightest guys.burzynskiclinic. ATHM: Any last thoughts? Dr Burzynski: Hopefully the problems which we face now. If you consider 24 000 genes which constitute a cancerous genome. Once we are successful. Of course. ATHM: Are there supplements or food components that you recommend that people with cancer should avoid? Dr Burzynski: Well. Burzynski. We are treating patients together with oncologists from all over the world. NO. Our goal is to identify the most important gene. you are not dealing with say five or seven varieties of breast cancer. So at this moment. To subscribe. If you are talking about. The rest of the club does not understand what we do at all and hate us. Use ISSN#1078-6791. But really.com ALTERNATIVE THERAPIES. We have a group of about 100 top oncologists. the driver gene. It’s not for cancer. ATHM: Have you had young scientists come to you because they are excited and interested by your work? Dr Burzynski: Absolutely. mAY/JUNE 2012. just to give you an example. please visit copyright. To share or copy this article. visit alternative-therapies. They would like to get rid of us. We have oncologists coming to us from various countries almost all the time to learn how to use our approach. will stop. ATHM: Do you think that understanding in the medical community about your research is improving with time or evolving? Dr Burzynski: Absolutely. All of this comes together as the scientific approach for the treatment of cancer. you have to find out what is the best for this individual patient. Every patient seems to have different combination of genes which cause the cancer. They all assume research must come from a big pharmaceutical company or big institutions. There are many other genes that are normal and are simply working in the direction of driver genes. For about 75% of patients. we have to convert oncologists one by one. But this crowd also will change if the breakthrough comes. And every patient who comes to us has a dietary consultation where we give him an indication of which diet is the best for him and which supplements he should use. and that’s what we do. They don’t believe something can come from a small clinic. We have young scientists who are working in laboratories. which is an amino acid that can stimulate some types of cancer. breast cancer. not much good came from these institutions within the last decade. just to make the next generation of antineoplastons. the senseless attacks. but only a few of these doctors will pay attention to what I have to say because I am not from a big medical institution. We are working on the next generation of antineoplastons by using nano technology and techniques. You are dealing with 100 000 varieties. L-glutamine is an amino acid to be avoided because it’s also extremely important for the development of cancer. If somebody would like to know more about our work. Conversations With Stanislaw R. But a number of doctors are beginning to understand what we do.This article is protected by copyright. then the amount of combinations is astronomical. Of course. MD. for instance. please visit our clinic.com L-glutamine. and then our approach will be accepted.com. and the number of those who would like to be trained in our strategy is increasing all the time. if you would like to do it right. then the network of genes which caused the cancer will collapse. 3 61 . a small research center. ATHM: Are different diets appropriate for different types of cancer? Dr Burzynski: For every patient. Unfortunately. That’s our main task. I am giving lectures at the oncology congresses. and the tumors will disappear. and they would like to join us. http://www. We have young oncologists who are very interested in what we do. 18. That is what we are looking for.
This action might not be possible to undo. Are you sure you want to continue?
We've moved you to where you read on your other device.
Get the full title to continue reading from where you left off, or restart the preview.